We compared the levels of transforming growth factor β1 (TGF-β1), vascular endothelial growth factor (VEGF) and other biochemical parameters in patients with type 1 diabetes mellitus with and without incipient diabetic nephropathy (iDN) and compared them with healthy control subjects. We also measured the effect of 3 and 6 months of ramipril treatment in diabetes patients with iDN. Compared with healthy controls, TGF-β1 levels were increased in both groups of diabetes patients, whereas VEGF was only elevated in patients with iDN. Ramipril did not have a significant effect on TGF-β1 or VEGF levels. We observed a significant decrease in microalbuminuria and cystatin C following ramipril treatment. Increased VEGF levels in patients with iDN suggest a role for this cytokine in the pathogenesis of diabetic nephropathy. Cystatin C would make a suitable marker for the screening and assessment of iDN, and for the evaluation of the therapeutic efficacy of drugs.
SchenaFPGesualdoL: Pathogenetic mechanism of diabetic nephropathy. J Am Soc Nephrol2005; 16: 30–33.
2.
YangBCrosDFOllerenshawM: Polymorphism of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications2003; 17: 1–6.
3.
YanSFRamasamyRBucciarelliLG: RAGE and its ligands: A lasting memory in diabetic complications?Diab Vasc Dis Res2004; 1: 10–20.
4.
PickupJCWillamsG: Textbook of Diabetes, 3rd edn.Oxford: Blackwell Science2003.
5.
WahabNASchaeferLWestonBS: Glomerulal expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia2005; 48: 2650–2660.
6.
ChambersRCLeoniPKaminskiN: Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol2003; 162: 533–546.
7.
BoyleJJ: Macrophage activation in atherosclerosis: Pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol2005; 3: 63–68.
8.
BacakovaLHergerJWilhelmJ: Influence of macrophages-modified collagen I on the adhesion and proliferation of vascular smooth muscle cells in culture. Physiol Res1999; 48: 341–351.
9.
ZavadovaELoercherAVerstovsekS: The role of macrophages in antitumor defense of patients with ovarian cancer. Hematol Oncol Clin N Am1999; 13: 135–144.
10.
SharmaKZiyadehFN: Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes1995; 44: 1139–1146.
11.
KanesakiYSuzukiDUeharaG: Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis2005; 45: 288–294.
12.
VrieseASTiltonRGElgerM: Antibodies against vascular endothelial factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol2001; 12: 993–1000.
13.
MonroziesBPRostaingLKamarN: The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure. Presse Med2002; 31: 1714–1720.
14.
VibertiGMogensenCEGroopLC: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA1994; 271: 275–279.
15.
The Microalbuminuria Captopril Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia1996; 39: 587–593.
16.
SharmaKEltayebBOMcGowanTA: Captopril-induced reduction of serum levels of TGF-beta 1 correlates with long-term renoprotection in insulin dependent diabetic patients. Am J Kidney Dis1999; 34: 951–954.
17.
TamaratRSilvestreJSDurieJS: Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest2002; 82: 747–756.
18.
YeXFYorikaNOdaH: Role of transforming growth factor-beta 1 and -beta 2 in ddY mouse nephropathy. J Int Med Res1997; 25: 141–145.
19.
ZdarskaDVavrinecJZavadovaE: Increased levels of TGF beta 1 in recently diagnosed diabetes mellitus in adults and in patients with diabetic complications. Diabetes2005; 54: A614.
20.
FloresLNafRHernáezR: Transforming growth factor beta 1 at clinical onset of Type 1 diabetes mellitus. A pilot study. Diabet Med2004; 21: 818–822.
21.
GilbertRECoxAWuLL: Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of ACE inhibition. Diabetes1998; 47: 414–422.
22.
SampsonMJDruryPL: Accurate estimation of glomerular filtration rate in diabetic nephropathy from age, body, weight, and serum creatinine. Diabetes Care1992; 15: 609–612.
23.
PerlemoiineCBeauviexMCRigalleauV: Interest of cystatin C in screening diabetic patients for early impairment of renal function. Metabolism2003; 52: 1258–1264.
24.
BuysschaertMJoudiIWallemecqP: Performance of serum cystatin-C versus serum creatinine in subjects with type 1 diabetes. Diabetes Care2003; 26: 1320.
25.
The Diabetes Control and Complications Trial Research Group: The effect of intensive insulin treatment of diabetes in the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med1993; 329: 977–986.
26.
MolichME: The relationship between glucose control and the development of diabetic nephropathy in type 1 diabetes. Semin Nephrol1997; 17: 101–103.
27.
MolyneauxLMConstantinoMIMcGillM: Better glycaemic control and risk reduction of diabetic complications in type 2 diabetes: Comparison with the DCCT. Diabetes Res Clin Pract1998; 42: 77–83.
28.
SteffesMW: Glycemic control and the initiation and progression of the complications of diabetes mellitus. Kidney Int1997; 63: S36–S39.
29.
BorderWANobleNA: Cytokines in kidney disease: The role of transforming growth factor-beta. Am J Kidney Dis1993; 22: 105–113.
